Balance Sheet

Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Insight Molecular Diagnostics (IMDX) Acquisitions (2020 - 2021)

Insight Molecular Diagnostics' Acquisitions history spans 2 years, with the latest figure at $607000.0 for Q1 2021.

On a quarterly basis, Acquisitions fell 90.19% to $607000.0 in Q1 2021 year-over-year; TTM through Dec 2021 was $607000.0, a 90.19% decrease, with the full-year FY2021 number at $607000.0, down 90.19% from a year prior.
Acquisitions hit $607000.0 in Q1 2021 for Insight Molecular Diagnostics, down from $6.2 million in the prior quarter.
Over the last five years, Acquisitions for IMDX hit a ceiling of $6.2 million in Q1 2020 and a floor of $607000.0 in Q1 2021.